Phosphagenics to sell bioElixia business
25 February, 2015 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has put its bioElixia range of cosmetic products up for sale as part of plans to focus on its core drug delivery business.
AusBiotech comments on draft IP Toolkit for research collaboration
24 February, 2015AusBiotech has made a submission to IP Australia on the draft IP Toolkit for research collaborations between research institutes and companies, where it said the draft IP Toolkit could offer useful guidance to SMEs who wish to engage in collaborations.
Anatara Lifesciences names new CEO
24 February, 2015 by Dylan Bushell-EmblingAnatara Lifesciences (ASX:ANR) has made three new executive appointments including a new CEO and has reported a 530% increase in its net loss for the first half of FY15.
Replacing leaky heart valves in situ
23 February, 2015Surgeons in Sydney have successfully replaced leaky mitral valves in two human hearts while they were still beating.
Saluda raises $10m for neuromodulation device
23 February, 2015 by Dylan Bushell-EmblingNICTA spinoff Saluda Medical has raised $10m in Series B funding to help develop Evoke, its neuromodulation device for treating chronic pain and other conditions.
Annual survey of Australia's biotech industry closing soon
19 February, 2015The annual AusBiotech CEO Industry Position Survey is in its final weeks of data collection and biotech industry leaders (CEOs, MDs) are urged to assist industry development with experiences, knowledge, key metrics and political insight.
Anatara's Detach reduces piglet mortality in farm trial
18 February, 2015 by Dylan Bushell-EmblingAnatara Lifesciences (ASX:ANR) said its Detach product was able to reduce piglet mortality compared with a placebo during an on-site trial at a Victorian farm.
Call for transitional arrangements for R&D Tax incentive cap
17 February, 2015The passage of legislation last week to cap claims on the Research and Development (R&D) Tax Incentive and its retrospective application to 1 July 2014 has prompted calls for the government to provide transitional arrangements for biotech companies abandoned in a difficult position.
Starpharma 1H losses grow on trial spending
17 February, 2015 by Dylan Bushell-EmblingStarpharma (ASX:SPL) reported a wider net loss for the first half of FY15 on increased clinical trial spending, but a capital raising left the company in an improved cash position.
Immuron licenses Travelan in China region
17 February, 2015 by Dylan Bushell-EmblingImmuron (ASX:IM) has licensed its Travelan product - a preventative treatment for travellers diarrhoea - in China and expects the market to eclipse sales of the product in its other regions combined.
PolyNovo names new CEO
16 February, 2015 by Dylan Bushell-EmblingPolyNovo (ASX:PNV) has appointed a new CEO and a regulatory affairs manager as it pursues commercialisation of its products in areas including wound and burns treatment.
CSL boosts half-year profit by 7%
13 February, 2015 by Dylan Bushell-EmblingCSL (ASX:CSL) has reported a net profit for the first half of FY15 of $890.3m, with sales increasing across all its core product segments.
Government joins forces with PUP and Xenophon to stifle biotech innovation
12 February, 2015The government's shock deal with the Palmer United Party and Independent Senator Xenophon to pass legislation in the Senate on Tuesday night to limit the Research and Development (R&D) Tax Incentive deals a further blow to Australia's innovation ecosystem and will impact large and small biotech companies, according to AusBiotech.
Mesoblast well funded despite rising losses
12 February, 2015 by Dylan Bushell-EmblingMesoblast (ASX:MSB) reported a 64% higher net loss for the half-year ending in December, but still ended the period in a strong cash position of $149.2m.
ResMed buys HME software vendor Jaysec
11 February, 2015ResMed (ASX:RMD) has acquired home medical equipment resupply software provider Jaysec and arranged to incorporate Brightree's billing software into its AirView patient management system.
